ST. JOSEPH, Mich., Jan. 6 /PRNewswire/ -- GeneGo, Inc., a leading provider of software and high quality manually curated databases for systems biology and pathway analysis, today announced that Bayer Schering Pharma AG has renewed its MetaCore licenses for another three years. Bayer Schering Pharma has programs for cancer, cardiovascular diseases and gynecological therapies and GeneGo has good coverage of these diseases and others. GeneGo is also in the process of building disease specific platforms in cancer and the cardiovascular area that include blueprint pathway maps for the disease, processes and mechanisms as well as offering public domain experimental data and disease ontologies.
"Bayer Schering Pharma was one of our first customers and we appreciate their loyalty," said Julie Bryant, Vice President of Business Development at GeneGo. "MetaCore is widely used in Bayer in multiple departments including bioinformatics, oncology, cardiology and women's health for data mining and analysis of multiple omics experimental data such as gene expression and proteomics."
About GeneGo, Inc.
GeneGo, Inc. develops systems biology technology such as compound based
pathway analysis, cheminformatics & bioinformatics software for life science
research. The original computational MetaDiscovery(TM) platform allows an
integration and expert analysis of different kinds of experimental data (mRNA
expression, proteomics, metabolomics, microRNA assays and other phenotypic
data) and relevant bioactive chemistry (metabolites, drugs, other xenobiotics)
within the framework of curated biological pathways and networks. GeneGo's
flagship product, MetaCore 5.1
|SOURCE GeneGo, Inc.|
Copyright©2009 PR Newswire.
All rights reserved